Drug cuts breast cancer risk for some post-menopausal women

Exemestane, sold as Aromasin, can reduce the risk of tumors in high- and moderate-risk post-menopausal women by 65% over a three-year period, researchers reported June 4 in the New England Journal of Medicine. Aromasin, a drug already used to treat breast cancer, does not appear to have the potentially lethal side effects associated with two anti-estrogen drugs (tamoxifen and raloxifene--sold as Evista) already approved for reducing breast tumor risk in health women.

hk-breast-cancer-drug-photo

( Ben Edwards / Getty Images )

Exemestane, sold as Aromasin, can reduce the risk of tumors in high- and moderate-risk post-menopausal women by 65% over a three-year period, researchers reported June 4 in the New England Journal of Medicine. Aromasin, a drug already used to treat breast cancer, does not appear to have the potentially lethal side effects associated with two anti-estrogen drugs (tamoxifen and raloxifene--sold as Evista) already approved for reducing breast tumor risk in health women.

Comments (0)

Add comments | Discussion FAQ

Currently there are no comments. Be the first to comment!

The Courant is using Facebook comments on stories. To comment on courant.com articles, sign into Facebook and enter your comment in the field below. Comments will appear in your Facebook News Feed unless you choose otherwise. To report spam or abuse, click the X next to the comment. For guidelines on commenting, click here.